Supervised consumption site enables cost savings by avoiding emergency services: a cost analysis study.
Cost analysis
Emergency services
Opioids
Overdose
Supervised consumption services
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
01
07
2020
accepted:
04
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
We report on a cost analysis study, using population level data to determine the emergency service costs avoided from emergency overdose management at supervised consumption services (SCS). We completed a cost analysis from a payer's perspective. In this setting, there is a single-payer model of service delivery. In Calgary, Canada, 'Safeworks Harm Reduction Program' was established in late 2017 and offers 24/7 access to SCS. The facility is a nurse-led service, available for client drop-in. We conducted a cost analysis for the entire duration of the program from November 2017 to January 2020, a period of 2 years and 3 months. We assessed costs using the following factors from government health databases: monthly operational costs of providing services for drug consumption, cost of providing ambulance pre-hospital care for clients with overdoses who could not be revived at the facility, cost of initial treatment in an emergency department, and benefit of costs averted from overdoses that were successfully managed at the SCS. The proportion of clients who have overdosed at the SCS has decreased steadily for the duration of the program. The number of overdoses that can be managed on site at the SCS has trended upward, currently 98%. Each overdose that is managed at the SCS produces approximately $1600 CAD in cost savings, with a savings of over $2.3 million for the lifetime of the program. Overdose management at an SCS creates cost savings by offsetting costs required for managing overdoses using emergency department and pre-hospital ambulance services.
Sections du résumé
BACKGROUND AND AIMS
We report on a cost analysis study, using population level data to determine the emergency service costs avoided from emergency overdose management at supervised consumption services (SCS).
DESIGN
We completed a cost analysis from a payer's perspective. In this setting, there is a single-payer model of service delivery.
SETTING
In Calgary, Canada, 'Safeworks Harm Reduction Program' was established in late 2017 and offers 24/7 access to SCS. The facility is a nurse-led service, available for client drop-in. We conducted a cost analysis for the entire duration of the program from November 2017 to January 2020, a period of 2 years and 3 months.
METHODS
We assessed costs using the following factors from government health databases: monthly operational costs of providing services for drug consumption, cost of providing ambulance pre-hospital care for clients with overdoses who could not be revived at the facility, cost of initial treatment in an emergency department, and benefit of costs averted from overdoses that were successfully managed at the SCS.
RESULTS
The proportion of clients who have overdosed at the SCS has decreased steadily for the duration of the program. The number of overdoses that can be managed on site at the SCS has trended upward, currently 98%. Each overdose that is managed at the SCS produces approximately $1600 CAD in cost savings, with a savings of over $2.3 million for the lifetime of the program.
CONCLUSION
Overdose management at an SCS creates cost savings by offsetting costs required for managing overdoses using emergency department and pre-hospital ambulance services.
Identifiants
pubmed: 35346223
doi: 10.1186/s12954-022-00609-5
pii: 10.1186/s12954-022-00609-5
pmc: PMC8959556
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Informations de copyright
© 2022. The Author(s).
Références
Harm Reduct J. 2017 May 12;14(1):29
pubmed: 28532488
Harm Reduct J. 2014 Nov 13;11(1):30
pubmed: 25395278
Int J Drug Policy. 2010 Jan;21(1):70-6
pubmed: 19423324
Addiction. 2019 Dec;114(12):2109-2115
pubmed: 31309637
Subst Abuse Treat Prev Policy. 2014 Aug 04;9:31
pubmed: 25091704
Addiction. 2016 Mar;111(3):475-89
pubmed: 26616368
Lancet. 2011 Apr 23;377(9775):1429-37
pubmed: 21497898
Ann Emerg Med. 1993 Mar;22(3):586-91
pubmed: 8442550
Addiction. 2010 Aug;105(8):1429-36
pubmed: 20653622
CMAJ. 2008 Nov 18;179(11):1143-51
pubmed: 19015565